<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601546</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2016-08/DL-01</org_study_id>
    <nct_id>NCT03601546</nct_id>
  </id_info>
  <brief_title>Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam</brief_title>
  <acronym>CoViet-C</acronym>
  <official_title>Feasibility of Implementing a Cohort of People Living With Hepatitis C in the Viet Tiep Hospital in Hai Phong, Vietnam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of implementing a cohort of patients
      with Hepatitis C in order to generate a larger cohort for future studies
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient inclusion rate</measure>
    <time_frame>End of study: 12 months</time_frame>
    <description>Number of patients included/number of eligible patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of missing data of patient variables</measure>
    <time_frame>Day 0-1</time_frame>
    <description>Current treatment, introduction of treatment, viral load, HCV genotype, fibrosis stage, HIV co-infection, drug consumption, alcohol consumption, methadone treatment,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lost to follow-up rate</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lost to follow-up rate</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Archival of all signed consent forms</measure>
    <time_frame>End of study: Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social-demographic characteristics of patients at inclusion</measure>
    <time_frame>Day 0</time_frame>
    <description>age, sex, weight, height, pregnancy test,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug and alcohol consumption,</measure>
    <time_frame>Day 0</time_frame>
    <description>type and amount</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment at inclusion</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>commencement of treat</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>initial HCV viral load,</measure>
    <time_frame>Day 0</time_frame>
    <description>UI/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV genotype</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis stage</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>Day 0</time_frame>
    <description>Copies/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte T4 level</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of CD4 lymphocytes/mm3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis stage</measure>
    <time_frame>Day 0</time_frame>
    <description>Fibroscan result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic ultrasound</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transaminase levels</measure>
    <time_frame>Day 0</time_frame>
    <description>Gamma-glutamyl transferase, Aspartate amino transferase, Alanine amino transferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV co-infection</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepititis B co-infection</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methadone treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access to health cover</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Commencement of treatment</measure>
    <time_frame>Day 1</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of treatment</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment side effects</measure>
    <time_frame>ay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early viral response</measure>
    <time_frame>Week 4</time_frame>
    <description>Undetectable HCV RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained viral response</measure>
    <time_frame>Week 12</time_frame>
    <description>Undetectable HCV RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV re-infection</measure>
    <time_frame>Month 12</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors associated with reinfection</measure>
    <time_frame>3 months after clearance</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Patients with HCV infection</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical examination</intervention_name>
    <description>Blood test and patient interview as for standard patient care</description>
    <arm_group_label>Patients with HCV infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      frozen plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Hepititis C recruited during consultation in the infections and tropical
        disease service of the Viet Tiep hospital in Hai Phong, Vietnam
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient is at least 18 years old

          -  The patient is HCV RNA positive

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Didier Laureillard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Didier Laureillard, MD</last_name>
    <phone>33.(0)04.66.68.41.49</phone>
    <email>didier.laureillard@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Viet Tiep</name>
      <address>
        <city>Hai Phong</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vu Hai Vinh, MD</last_name>
      <phone>+84.(0)9.84.77.70.03</phone>
      <email>vinhvuhai@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vu Hai Vinh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

